SK282071B6 - Tableta dispergovateľná vo vode a spôsob jej prípravy - Google Patents
Tableta dispergovateľná vo vode a spôsob jej prípravy Download PDFInfo
- Publication number
- SK282071B6 SK282071B6 SK817-93A SK81793A SK282071B6 SK 282071 B6 SK282071 B6 SK 282071B6 SK 81793 A SK81793 A SK 81793A SK 282071 B6 SK282071 B6 SK 282071B6
- Authority
- SK
- Slovakia
- Prior art keywords
- tablet
- weight
- acyclovir
- tablets
- tablet according
- Prior art date
Links
- 239000004565 water dispersible tablet Substances 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title description 10
- 239000003826 tablet Substances 0.000 claims abstract description 197
- 239000004927 clay Substances 0.000 claims abstract description 63
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims abstract description 59
- 229960004150 aciclovir Drugs 0.000 claims abstract description 59
- 239000008187 granular material Substances 0.000 claims abstract description 58
- 230000008961 swelling Effects 0.000 claims abstract description 33
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 239000004480 active ingredient Substances 0.000 claims abstract 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 36
- 239000000203 mixture Substances 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 22
- 239000007884 disintegrant Substances 0.000 claims description 20
- 235000019359 magnesium stearate Nutrition 0.000 claims description 19
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 18
- 239000011230 binding agent Substances 0.000 claims description 17
- -1 glidants Substances 0.000 claims description 14
- 229910052901 montmorillonite Inorganic materials 0.000 claims description 14
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 claims description 13
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 claims description 12
- 239000000945 filler Substances 0.000 claims description 12
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 12
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 11
- 239000008109 sodium starch glycolate Substances 0.000 claims description 11
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 229910021647 smectite Inorganic materials 0.000 claims description 10
- 239000000440 bentonite Substances 0.000 claims description 9
- 229910000278 bentonite Inorganic materials 0.000 claims description 9
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims description 9
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 8
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 8
- 239000004353 Polyethylene glycol 8000 Substances 0.000 claims description 7
- 239000011247 coating layer Substances 0.000 claims description 7
- 238000007906 compression Methods 0.000 claims description 7
- 230000006835 compression Effects 0.000 claims description 7
- 229940085678 polyethylene glycol 8000 Drugs 0.000 claims description 7
- 235000019446 polyethylene glycol 8000 Nutrition 0.000 claims description 7
- 229910052625 palygorskite Inorganic materials 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 6
- 229960000892 attapulgite Drugs 0.000 claims description 5
- 229920000881 Modified starch Polymers 0.000 claims description 4
- 239000000969 carrier Substances 0.000 claims description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 3
- 229910000276 sauconite Inorganic materials 0.000 claims description 3
- 235000019354 vermiculite Nutrition 0.000 claims description 3
- KWLMIXQRALPRBC-UHFFFAOYSA-L hectorite Chemical compound [Li+].[OH-].[OH-].[Na+].[Mg+2].O1[Si]2([O-])O[Si]1([O-])O[Si]([O-])(O1)O[Si]1([O-])O2 KWLMIXQRALPRBC-UHFFFAOYSA-L 0.000 claims description 2
- 229910000271 hectorite Inorganic materials 0.000 claims description 2
- 229910052902 vermiculite Inorganic materials 0.000 claims description 2
- 239000010455 vermiculite Substances 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims 2
- 239000006185 dispersion Substances 0.000 description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- 150000001875 compounds Chemical class 0.000 description 24
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 19
- 238000005469 granulation Methods 0.000 description 16
- 230000003179 granulation Effects 0.000 description 16
- 229920003081 Povidone K 30 Polymers 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 239000011777 magnesium Substances 0.000 description 12
- 229940069328 povidone Drugs 0.000 description 12
- 229920002472 Starch Polymers 0.000 description 11
- 239000007919 dispersible tablet Substances 0.000 description 11
- 239000002245 particle Substances 0.000 description 11
- 229940032147 starch Drugs 0.000 description 11
- 239000008107 starch Substances 0.000 description 11
- 235000019698 starch Nutrition 0.000 description 11
- 238000009472 formulation Methods 0.000 description 10
- 238000002156 mixing Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 239000007916 tablet composition Substances 0.000 description 9
- 239000011248 coating agent Substances 0.000 description 8
- 238000000576 coating method Methods 0.000 description 8
- 230000009747 swallowing Effects 0.000 description 8
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 7
- 239000001768 carboxy methyl cellulose Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 239000000314 lubricant Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- 239000002734 clay mineral Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- 208000007514 Herpes zoster Diseases 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 235000010356 sorbitol Nutrition 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- 229920003084 Avicel® PH-102 Polymers 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 230000001055 chewing effect Effects 0.000 description 2
- 239000008119 colloidal silica Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 2
- 229960001848 lamotrigine Drugs 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000010445 mica Substances 0.000 description 2
- 229910052618 mica group Inorganic materials 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 150000004760 silicates Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 229910018134 Al-Mg Inorganic materials 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 229910018467 Al—Mg Inorganic materials 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 101100420681 Caenorhabditis elegans tir-1 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241001408197 Eois Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000001688 Herpes Genitalis Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920003085 Kollidon® CL Polymers 0.000 description 1
- 241000917703 Leia Species 0.000 description 1
- 229910003023 Mg-Al Inorganic materials 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 244000288157 Passiflora edulis Species 0.000 description 1
- 235000000370 Passiflora edulis Nutrition 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920003110 Primojel Polymers 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 244000235659 Rubus idaeus Species 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- 241000238370 Sepia Species 0.000 description 1
- 239000004113 Sepiolite Substances 0.000 description 1
- 239000004990 Smectic liquid crystal Substances 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- GANNOFFDYMSBSZ-UHFFFAOYSA-N [AlH3].[Mg] Chemical class [AlH3].[Mg] GANNOFFDYMSBSZ-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- VNSBYDPZHCQWNB-UHFFFAOYSA-N calcium;aluminum;dioxido(oxo)silane;sodium;hydrate Chemical compound O.[Na].[Al].[Ca+2].[O-][Si]([O-])=O VNSBYDPZHCQWNB-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical class OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- JYIMWRSJCRRYNK-UHFFFAOYSA-N dialuminum;disodium;oxygen(2-);silicon(4+);hydrate Chemical compound O.[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[Na+].[Na+].[Al+3].[Al+3].[Si+4] JYIMWRSJCRRYNK-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007580 dry-mixing Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229940065410 feldene Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229910021485 fumed silica Inorganic materials 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 201000004946 genital herpes Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229940094522 laponite Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- XCOBTUNSZUJCDH-UHFFFAOYSA-B lithium magnesium sodium silicate Chemical compound [Li+].[Li+].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3 XCOBTUNSZUJCDH-UHFFFAOYSA-B 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000003921 particle size analysis Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229910052615 phyllosilicate Inorganic materials 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229910000275 saponite Inorganic materials 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000011555 saturated liquid Substances 0.000 description 1
- 229910052624 sepiolite Inorganic materials 0.000 description 1
- 235000019355 sepiolite Nutrition 0.000 description 1
- 238000005029 sieve analysis Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 150000004685 tetrahydrates Chemical class 0.000 description 1
- 229910001771 thuringite Inorganic materials 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- AZJYLVAUMGUUBL-UHFFFAOYSA-A u1qj22mc8e Chemical compound [F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].O=[Si]=O.O=[Si]=O.O=[Si]=O.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3 AZJYLVAUMGUUBL-UHFFFAOYSA-A 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB919102019A GB9102019D0 (en) | 1991-01-30 | 1991-01-30 | Pharmaceutical formulations |
| GB919124807A GB9124807D0 (en) | 1991-11-22 | 1991-11-22 | Pharmaceutical formulations |
| GB919124803A GB9124803D0 (en) | 1991-11-22 | 1991-11-22 | Pharmaceutical formulations |
| GB919125005A GB9125005D0 (en) | 1991-11-25 | 1991-11-25 | Pharmaceutical formulations |
| PCT/GB1992/000163 WO1992013527A1 (en) | 1991-01-30 | 1992-01-29 | Water-dispersible tablets |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK81793A3 SK81793A3 (en) | 1994-03-09 |
| SK282071B6 true SK282071B6 (sk) | 2001-10-08 |
Family
ID=27450613
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1655-2000A SK282072B6 (sk) | 1991-01-30 | 1992-01-29 | Tableta s obsahom lamotrigínu dispergovateľná vo vode a spôsob jej prípravy |
| SK817-93A SK282071B6 (sk) | 1991-01-30 | 1992-01-29 | Tableta dispergovateľná vo vode a spôsob jej prípravy |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1655-2000A SK282072B6 (sk) | 1991-01-30 | 1992-01-29 | Tableta s obsahom lamotrigínu dispergovateľná vo vode a spôsob jej prípravy |
Country Status (37)
| Country | Link |
|---|---|
| US (2) | US5556639A (da) |
| EP (1) | EP0522128B1 (da) |
| JP (2) | JP3118255B2 (da) |
| KR (1) | KR100190254B1 (da) |
| AT (1) | ATE133068T1 (da) |
| AU (2) | AU653203B2 (da) |
| BE (1) | BE1004461A5 (da) |
| BG (1) | BG61665B2 (da) |
| CA (1) | CA2098108C (da) |
| CH (1) | CH685978A5 (da) |
| CY (1) | CY2007A (da) |
| CZ (1) | CZ286723B6 (da) |
| DE (2) | DE69207656T2 (da) |
| DK (2) | DK0522128T3 (da) |
| ES (2) | ES2080641B1 (da) |
| FI (2) | FI111605B (da) |
| FR (1) | FR2671970B1 (da) |
| GB (1) | GB2257363B (da) |
| GR (1) | GR3019545T3 (da) |
| HK (1) | HK78597A (da) |
| HU (2) | HU221677B1 (da) |
| IE (1) | IE77165B1 (da) |
| IL (1) | IL100796A (da) |
| IT (1) | IT1257473B (da) |
| LU (1) | LU88323A1 (da) |
| MX (1) | MX9200412A (da) |
| MY (2) | MY110880A (da) |
| NL (1) | NL9220009A (da) |
| NO (1) | NO306697B1 (da) |
| PA (1) | PA7695401A1 (da) |
| PL (1) | PL169106B1 (da) |
| RU (1) | RU2106861C1 (da) |
| SA (1) | SA92120365B1 (da) |
| SE (1) | SE9302363D0 (da) |
| SK (2) | SK282072B6 (da) |
| UA (1) | UA37214C2 (da) |
| WO (1) | WO1992013527A1 (da) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9424766D0 (en) * | 1994-12-07 | 1995-02-08 | Wellcome Found | Pharmaceutical composition |
| ES2079327B1 (es) * | 1994-12-13 | 1996-08-01 | Lilly Sa | Formulaciones farmaceuticas de cefaclor. |
| GB9501127D0 (en) * | 1995-01-20 | 1995-03-08 | Wellcome Found | Tablet |
| GB9518465D0 (en) * | 1995-09-09 | 1995-11-08 | Smithkline Beecham Seiyaku Kk | Pharmaceuticals |
| GB9600847D0 (en) * | 1996-01-16 | 1996-03-20 | Smithkline Beecham Plc | Pharmaceuticals |
| FR2759706B1 (fr) * | 1997-02-18 | 2003-11-28 | Alain Perrier | Procede de traitement de l'argile a des fins therapeutiques et produits obtenus par ce procede |
| US6129932A (en) * | 1997-09-05 | 2000-10-10 | Merck & Co., Inc. | Compositions for inhibiting platelet aggregation |
| US5955107A (en) * | 1997-12-12 | 1999-09-21 | Fmc Corporation | Pharmaceutical suspension tablet compositions |
| DE19820801A1 (de) * | 1998-05-09 | 1999-11-25 | Gruenenthal Gmbh | Orale Arzneiformen mit reproduzierbarer Wirkstofffreisetzung von Gatifloxacin oder pharmazeutisch verwendbaren Salzen oder Hydraten |
| AU764742B2 (en) | 1998-11-10 | 2003-08-28 | Teva Pharmaceutical Industries Ltd. | Dispersible compositions containing L-DOPA ethyl ester |
| PE20001302A1 (es) * | 1998-11-27 | 2000-11-30 | Hoffmann La Roche | Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida |
| DE60020680T2 (de) * | 1999-02-17 | 2006-05-04 | Kyowa Hakko Kogyo Co., Ltd. | Tabletten und verfahren zur tablettenherstellung |
| US6399591B1 (en) * | 2000-01-19 | 2002-06-04 | Yung-Shin Pharmaceutical Ind. Co., Ltd. | Chargeable pharmaceutical tablets |
| GB0010446D0 (en) * | 2000-04-28 | 2000-06-14 | Glaxo Wellcome Kk | Pharmaceutical formulation |
| US6555145B1 (en) * | 2000-06-06 | 2003-04-29 | Capricorn Pharma, Inc. | Alternate encapsulation process and products produced therefrom |
| US6365209B2 (en) * | 2000-06-06 | 2002-04-02 | Capricorn Pharma, Inc. | Confectionery compositions and methods of making |
| US6358526B1 (en) | 2000-08-16 | 2002-03-19 | Rexall Sundown | Method of making tablets and tablet compositions produced therefrom |
| EA005497B1 (ru) * | 2001-01-03 | 2005-02-24 | Берлин Хеми Аг | Применение фармацевтической композиции, содержащей бривудин, для лечения герпесвирусных инфекций |
| US7939102B2 (en) * | 2002-06-07 | 2011-05-10 | Torrent Pharmaceuticals Ltd. | Controlled release formulation of lamotrigine |
| US8637512B2 (en) | 2002-07-29 | 2014-01-28 | Glaxo Group Limited | Formulations and method of treatment |
| GB0223978D0 (en) * | 2002-10-15 | 2002-11-20 | Novartis Ag | Organic compound |
| US8992980B2 (en) * | 2002-10-25 | 2015-03-31 | Boehringer Ingelheim Vetmedica Gmbh | Water-soluble meloxicam granules |
| US20040109889A1 (en) * | 2002-12-04 | 2004-06-10 | Bunick Frank J. | Surface treatment composition for soft substrates |
| WO2004082587A2 (en) * | 2003-03-21 | 2004-09-30 | Ranbaxy Laboratories Limited | Stable lamotrigine pharmaceutical compositions and processes for their preparation |
| US7282217B1 (en) | 2003-08-29 | 2007-10-16 | Kv Pharmaceutical Company | Rapidly disintegrable tablets |
| EP1700591A4 (en) | 2003-12-01 | 2011-08-03 | Takeda Pharmaceutical | PROCESS FOR TREATING SOLID PHARMACEUTICAL PREPARATION PRIOR TO PRINTING AND SOLID PHARMACEUTICAL PREPARATION SUBJECT TO PROCESSING BEFORE PRINTING |
| US8309103B2 (en) * | 2004-01-22 | 2012-11-13 | Alparis, S.A. De C.V. | Association of fluconazole-tinidazole for the treatment of vaginal infections, its composition, preparation process and usage |
| EP1568369A1 (en) | 2004-02-23 | 2005-08-31 | Boehringer Ingelheim Vetmedica Gmbh | Use of meloxicam for the treatment of respiratory diseases in pigs |
| US20070196477A1 (en) * | 2004-04-30 | 2007-08-23 | Withiam Michael C | Rapidly dissolving tablets comprising low surface area calcium phosphates |
| US20050244493A1 (en) * | 2004-04-30 | 2005-11-03 | Withiam Michael C | Rapidly disintegrating tablets comprising calcium carbonate |
| US20050244347A1 (en) * | 2004-04-30 | 2005-11-03 | Mehra Dev K | Oral care products comprising calcium phosphates |
| CN100340235C (zh) * | 2004-05-21 | 2007-10-03 | 山东绿叶制药有限公司 | 蒙脱石分散片及其制备工艺 |
| US20060008492A1 (en) * | 2004-07-09 | 2006-01-12 | Pablo Janowicz | Composition and method for delivering chemical agent to insects |
| DE102004042139B4 (de) * | 2004-08-31 | 2009-06-10 | Aristocon Verwaltungs- Gmbh | Perorale Darreichungsformen zur Erzielung eines Retardierungseffektes nach der Arzneimitteleinnahme mit einer Mahlzeit |
| JP2008531509A (ja) * | 2005-02-25 | 2008-08-14 | エフ．ホフマン−ラ ロシュ アーゲー | 医薬品成分の改良された分散性を有する錠剤 |
| IS7724A (is) * | 2005-03-02 | 2006-09-03 | Actavis Group | Samsetning á töflum með hraða sundrun sem innihalda þungt magnesíum karbónat |
| AU2006263338A1 (en) * | 2005-06-29 | 2007-01-04 | Panacea Biotec Ltd. | Pharmaceutical sustained release compositions and processes thereof |
| EP1906937B1 (en) | 2005-07-22 | 2016-10-19 | Rubicon Research Pvt Ltd. | Novel dispersible tablet composition |
| SG166115A1 (en) * | 2005-09-30 | 2010-11-29 | Boehringer Ingelheim Vetmed | Pharmaceutical preparation containing meloxicam |
| FR2912059B1 (fr) * | 2007-02-06 | 2013-04-05 | Scras | Utilisation d'argiles pour le traitement de la maladie coeliaque |
| US20100016322A1 (en) * | 2007-02-28 | 2010-01-21 | Nagesh Nagaraju | Water Dispersible Pharmaceutical Formulation and Process for Preparing The Same |
| GB0708929D0 (en) * | 2007-05-09 | 2007-06-20 | Glaxosmithkline Consumer Healt | Composition |
| GB0709541D0 (en) * | 2007-05-17 | 2007-06-27 | Jagotec Ag | Pharmaceutical excipient |
| TWI547282B (zh) * | 2007-07-02 | 2016-09-01 | 愛戴爾製藥股份有限公司 | 樂命達之口服分解錠劑組合物 |
| US20090022789A1 (en) * | 2007-07-18 | 2009-01-22 | Supernus Pharmaceuticals, Inc. | Enhanced formulations of lamotrigine |
| WO2009063484A2 (en) * | 2007-08-03 | 2009-05-22 | Alkem Laboratories Ltd | Stable pharmaceutical composition of lamotrigine |
| EP2100595A1 (en) * | 2008-03-10 | 2009-09-16 | The Procter and Gamble Company | Compressed tablets |
| JP2011526598A (ja) * | 2008-07-02 | 2011-10-13 | ビーエーエスエフ ソシエタス・ヨーロピア | 錠剤のコーティング方法 |
| HUE041795T2 (hu) * | 2010-08-31 | 2019-05-28 | Toray Industries | Bevonószer szilárd gyógyszerészeti készítményhez, gyógyszerészeti filmkészítmény, és bevonatos szilárd gyógyszerészeti készítmény |
| USD666097S1 (en) | 2010-11-01 | 2012-08-28 | Colgate-Palmolive Company | Cap for a container |
| USD666492S1 (en) | 2010-11-01 | 2012-09-04 | Colgate-Palmolive Company | Cap for a container |
| USD666098S1 (en) | 2010-11-01 | 2012-08-28 | Colgate-Palmolive Company | Cap for a container |
| USD666096S1 (en) | 2010-11-01 | 2012-08-28 | Colgate-Palmolive Company | Cap for a container |
| USD666493S1 (en) | 2010-11-01 | 2012-09-04 | Colgate-Palmolive Company | Cap for a container |
| USD666099S1 (en) | 2010-11-01 | 2012-08-28 | Colgate-Palmolive Company | Cap for a container |
| RU2462243C1 (ru) * | 2011-08-17 | 2012-09-27 | Вемур Инвестментс Лимитед | Средство для снятия похмельного синдрома |
| RU2558091C2 (ru) * | 2013-07-04 | 2015-07-27 | Общество с ограниченной ответственностью "Трейдсервис" | Диспергируемая таблетка смектита диоктаэдрического и способ ее получения |
| JP2019530727A (ja) | 2016-10-11 | 2019-10-24 | オクタ ファーマシューティカルズ | ラモトリギンを含む経口懸濁液用の粉末 |
| CN107115304B (zh) * | 2017-04-10 | 2019-02-26 | 浙江寿仙谷医药股份有限公司 | 一种去壁灵芝孢子粉片剂及其制备方法 |
| ES2930376T3 (es) * | 2017-12-08 | 2022-12-09 | Hoffmann La Roche | Formulación farmacéutica |
Family Cites Families (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB777516A (en) * | 1955-04-14 | 1957-06-26 | Griffiths Hughes Ltd E | Improvements in or relating to the production of tablets by pressure |
| GB837451A (en) * | 1956-02-20 | 1960-06-15 | Arner Co Inc | Sustained release therapeutic composition and process of preparing same |
| US3432593A (en) * | 1963-09-18 | 1969-03-11 | Key Pharm Inc | Delayed and sustained release type pharmaceutical preparation |
| US3427379A (en) * | 1966-01-13 | 1969-02-11 | Hoffmann La Roche | Dextromethorphan and benzyl alcohol hard candy lozenges free from opaqueness and/or tiny entrapped air bubbles |
| US3567819A (en) * | 1969-01-30 | 1971-03-02 | Hoffmann La Roche | Cold tablet |
| DE2016622A1 (en) * | 1970-04-08 | 1971-10-21 | Farbenfabriken Bayer Ag, 5090 Leverkusen | Anthelmintic benzimidazole deriv |
| NL149711B (nl) * | 1970-06-15 | 1976-06-15 | Sumitomo Chemical Co | Werkwijze voor het vervaardigen van pillen, alsmede de aldus vervaardigde pillen. |
| US4072535A (en) * | 1970-12-28 | 1978-02-07 | A. E. Staley Manufacturing Company | Precompacted-starch binder-disintegrant-filler material for direct compression tablets and dry dosage capsules |
| FR2183546B1 (da) * | 1972-05-10 | 1975-06-20 | Servier Lab | |
| DE2251249A1 (de) * | 1972-10-19 | 1974-05-02 | Hoechst Ag | Verfahren zur herstellung von penicillin-verbindungen enthaltenden tabletten |
| US4209513A (en) * | 1974-02-14 | 1980-06-24 | Burroughs Wellcome Co. | Tablet formulation |
| DE2416903A1 (de) * | 1974-04-06 | 1975-10-09 | Bayer Ag | Verwendung von schmelzverspruehtem kugelfoermigem phenacetingranulat zur herstellung von tabletten im direkttablettierverfahren |
| JPS5154918A (en) * | 1974-10-08 | 1976-05-14 | Nippon Kayaku Kk | Jozaino seizoho |
| GB1533243A (en) * | 1975-02-13 | 1978-11-22 | Wellcome Found | Tablet formulation |
| CH630257A5 (en) * | 1975-03-17 | 1982-06-15 | Hoffmann La Roche | Sustained release formulation |
| US4086335A (en) * | 1975-10-29 | 1978-04-25 | Bruscato Frank N | Pharmaceutical tablets containing chitin as a disintegrant |
| GB1548022A (en) * | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
| GB1567392A (en) * | 1977-02-22 | 1980-05-14 | Farmaceutici Italia | Daunorubicin derivatives |
| AU508480B2 (en) * | 1977-04-13 | 1980-03-20 | Asahi Kasei Kogyo Kabushiki Kaisha | Microcrystalline cellulose excipient and pharmaceutical composition containing thesame |
| CA1097233A (en) * | 1977-07-20 | 1981-03-10 | George K. E. Gregory | Packages |
| GB1601833A (en) * | 1978-02-06 | 1981-11-04 | Wellcome Found | Antacid formulation |
| JPS54129129A (en) * | 1978-03-30 | 1979-10-06 | Sankyo Co Ltd | Powdered pesticide having suppressed static electrification |
| DE2845326C2 (de) * | 1978-10-18 | 1985-05-23 | Beiersdorf Ag, 2000 Hamburg | Verwendung einer spezifischen mikrodispersen, amorphen, porösen Kieselsäure zur Herstellung von Digoxin enthaltenden Tabletten mit stark beschleunigter Wirkstoff-Freisetzung |
| DE2849494A1 (de) * | 1978-11-15 | 1980-05-29 | Voss Gunter M | Verfahren zur herstellung von arzneimittel-formlingen |
| CA1112643A (en) * | 1979-06-01 | 1981-11-17 | Martin G. Baxter | 3,5-diamino-6-phenyl-1,2,4-triazines |
| US4251518A (en) * | 1979-07-03 | 1981-02-17 | Ralston Purina Company | Method of preparing readily disintegrable pharmaceutical compositions |
| JPS56127309A (en) * | 1980-03-11 | 1981-10-06 | Dai Ichi Seiyaku Co Ltd | Zeolite support for ascorbic acid |
| JPS5711913A (en) * | 1980-06-24 | 1982-01-21 | Tsumura Juntendo Inc | Preparation of hard-capsule of herb medicine |
| JPS5711911A (en) * | 1980-06-25 | 1982-01-21 | Tsumura Juntendo Inc | Preparation of herb medicine tablet |
| US4304773A (en) * | 1980-06-26 | 1981-12-08 | E. R. Squibb & Sons, Inc. | Novel bendroflumethiazide formulations and method |
| JPS5756434A (en) * | 1980-09-22 | 1982-04-05 | Kao Corp | Stabilized foamable composition |
| EP0052076B1 (de) * | 1980-11-12 | 1985-05-29 | Ciba-Geigy Ag | Schnellzerfallende Arzneimittel-Presslinge |
| US4369308A (en) * | 1981-07-24 | 1983-01-18 | National Starch And Chemical Corporation | Low swelling starches as tablet disintegrants |
| HU189534B (en) * | 1981-09-09 | 1986-07-28 | Chinoin Rt.,Hu | Process for producing new tablets containing cyclodextrin polymer as desintegrator |
| US4414198A (en) * | 1982-04-23 | 1983-11-08 | Joseph Michaelson | Rapidly disintegrable tablet composition and method |
| GB2119355B (en) * | 1982-04-29 | 1985-05-09 | Scras | Modified clays |
| IL68311A0 (en) * | 1982-04-29 | 1983-07-31 | Scras | Modified clays,their preparation and pharmaceutical compositions containing them |
| GR79340B (da) * | 1982-07-06 | 1984-10-22 | Sterwin Ag | |
| US4517179A (en) * | 1983-04-29 | 1985-05-14 | Pennwalt Corporation | Rapid dissolving, uniform drug compositions and their preparation |
| US4600579A (en) * | 1983-06-07 | 1986-07-15 | Mallinckrodt, Inc. | N-acetyl-p-aminophenol compositions containing partially gelatinized starch and method for preparing same |
| CH658188A5 (de) * | 1984-03-23 | 1986-10-31 | Ciba Geigy Ag | Lagerstabile schnellzerfallende pharmazeutische presslinge. |
| US4661521A (en) * | 1984-04-30 | 1987-04-28 | Mallinckrodt, Inc. | Direct tableting acetaminophen compositions |
| DE3505433A1 (de) * | 1985-02-16 | 1986-08-21 | Basf Ag, 6700 Ludwigshafen | Direkttablettierhilfsmittel |
| US4631305A (en) * | 1985-03-22 | 1986-12-23 | The Upjohn Company | Polymeric material as a disintegrant in a compressed tablet |
| EP0199855A1 (en) * | 1985-05-02 | 1986-11-05 | Gist-Brocades N.V. | Tablets comprising tromethoprim and a sulfonamide |
| WO1987001936A1 (en) * | 1985-09-25 | 1987-04-09 | Gerhard Gergely | Desintegration tablet and process for its manufacture |
| US4781925A (en) * | 1986-03-06 | 1988-11-01 | American Home Products Corporation | Calcium supplement compressed tablets |
| JPS62227729A (ja) * | 1986-03-31 | 1987-10-06 | Kanegafuchi Chem Ind Co Ltd | 断熱材 |
| KR880701098A (ko) * | 1986-04-01 | 1988-07-25 | 로버어트 에이 아미테이지 | 메틸프레드니솔론/소디움 카르복시메틸 전분 정제 조성물 |
| GB8613183D0 (en) * | 1986-05-30 | 1986-07-02 | Wellcome Found | Triazine salt |
| DE3635864A1 (de) * | 1986-06-26 | 1988-05-05 | Gerhard Gergely | Verfahren zum herstellen eines brausegranulates, danach hergestelltes brausegranulat sowie dessen verwendung |
| US4757090A (en) * | 1986-07-14 | 1988-07-12 | Mallinckrodt, Inc. | Direct tableting acetaminophen compositions |
| KR960001372B1 (ko) * | 1986-09-24 | 1996-01-26 | 예일 유니버시티 | 레트로비루스로 감염된 환자의 치료에 사용되는 2',3'-디디옥시사이티딘-2'-엔(2',3'-디디옥시-2',3'-디디하이드로사이티딘)의 항생물질 |
| GB8624628D0 (en) * | 1986-10-14 | 1986-11-19 | Scras | Soluble/splitable tablets |
| US4771077A (en) * | 1986-10-21 | 1988-09-13 | American Home Products Corporation (Del.) | Spray dried acetaminophen |
| GB8628359D0 (en) * | 1986-11-27 | 1986-12-31 | Zyma Sa | Galenical formulation |
| ES2061623T3 (es) * | 1987-03-02 | 1994-12-16 | Brocades Pharma Bv | Procedimiento para la obtencion de una composicion farmaceutica y un granulado farmaceutico. |
| ATE73328T1 (de) * | 1987-05-08 | 1992-03-15 | Smith Kline French Lab | Pharmazeutische zusammensetzungen. |
| US4904477A (en) * | 1987-07-08 | 1990-02-27 | American Home Products Corporation | Spray dried ibuprofen compositions |
| ATE68346T1 (de) * | 1987-07-22 | 1991-11-15 | Farvalsa Ag | Feuchtigkeitsstabile feste valproinsaeurezubereitung und verfahren zu ihrer herstellung. |
| JP2527973B2 (ja) * | 1987-08-05 | 1996-08-28 | 株式会社資生堂 | 球状粘土鉱物及びその製造方法 |
| DE3806633A1 (de) * | 1987-09-01 | 1989-03-09 | Bayer Ag | Antivirales mittel |
| US4837031A (en) * | 1987-09-17 | 1989-06-06 | Mallinckrodt, Inc. | Compositions containing ibuprofen |
| JP2537062B2 (ja) * | 1987-10-02 | 1996-09-25 | 株式会社資生堂 | 薬剤組成物 |
| US4999200A (en) * | 1987-12-09 | 1991-03-12 | Marion Laboratories | Psyllium tablet composition, method of manufacture and method of use |
| ES2060737T3 (es) * | 1988-02-25 | 1994-12-01 | Yamanouchi Europ Bv | Procedimiento de preparacion de un granulado farmaceutico. |
| US4910023A (en) * | 1988-06-09 | 1990-03-20 | Warner-Lambert Company | Drug in combination with flavor masking agent and method for making same |
| YU120988A (en) * | 1988-06-23 | 1990-06-30 | Lek Tovarna Farmacevtskih | Process for preparing new dispersion pills of cimetidine |
| IT1226549B (it) * | 1988-07-12 | 1991-01-24 | Resa Farma | Composizioni farmaceutiche ad attivita' analgesica ed antiinfiammatoria per uso orale, dotate di ottima palatabilita' ed esenti da effetti irritanti sulle mucose. |
| YU183988A (en) * | 1988-09-30 | 1990-08-31 | Lek Tovarna Farmacevtskih | Process for preparing dispersion pills of dihydroergotoxine |
| JPH02111620A (ja) * | 1988-10-21 | 1990-04-24 | Kunimine Kogyo Kk | 水中分散性粒剤 |
| US4965072A (en) * | 1988-11-03 | 1990-10-23 | Miles Inc. | Granulating composition and method |
| US5073377A (en) * | 1988-11-03 | 1991-12-17 | Miles Inc. | Method of preparing oral dosage forms with a granulating composition |
| JPH02145501A (ja) * | 1988-11-25 | 1990-06-05 | Sanyo Chem Ind Ltd | 殺生剤粒剤組成物 |
| FI895821A0 (fi) * | 1988-12-07 | 1989-12-05 | Wellcome Found | Farmaceutiskt aktiva cns foereningar. |
| US4925676A (en) * | 1989-02-02 | 1990-05-15 | Warner-Lambert Company | Extended release gemfibrozil composition |
| US4927639A (en) * | 1989-02-02 | 1990-05-22 | Warner-Lambert Company | Modified release gemfibrozil composition |
| ES2055894T3 (es) * | 1989-04-07 | 1994-09-01 | Ciba Geigy Ag | Concentrados de sustancias activas pesticidas y su preparacion. |
| US4970078A (en) * | 1989-05-25 | 1990-11-13 | Aqualon Company | Crosslinked carboxymethyguar tablet disintegrant |
| DK0490920T3 (da) * | 1989-09-07 | 1994-04-25 | Gerhard Gergely | Mavesyrebindende farmaceutisk præparat |
| US5037658A (en) * | 1989-09-14 | 1991-08-06 | Hoechst-Roussel Pharmaceuticals, Inc. | Direct dry compressible acetaminophen composition |
| US5064656A (en) * | 1989-11-14 | 1991-11-12 | Dr. Gergely & Co. | Uncoated pharmaceutical reaction tablet |
| US5136080A (en) * | 1989-12-04 | 1992-08-04 | Burroughs Wellcome Co. | Nitrile compounds |
| JP3069665B2 (ja) * | 1990-03-15 | 2000-07-24 | 住友化学工業株式会社 | 農業用粒状水和剤組成物 |
| GB9012311D0 (en) * | 1990-06-01 | 1990-07-18 | Wellcome Found | Pharmacologically active cns compounds |
| GB9012316D0 (en) * | 1990-06-01 | 1990-07-18 | Wellcome Found | Pharmacologically active cns compounds |
| US5087454A (en) * | 1990-07-30 | 1992-02-11 | American Home Products Corporation | Ibuprofen tablet |
| GB9025372D0 (en) * | 1990-11-22 | 1991-01-09 | Nat Res Dev | Pharmaceutical dosage forms |
-
1992
- 1992-01-29 SK SK1655-2000A patent/SK282072B6/sk unknown
- 1992-01-29 NL NL9220009A patent/NL9220009A/nl active Search and Examination
- 1992-01-29 DE DE69207656T patent/DE69207656T2/de not_active Expired - Lifetime
- 1992-01-29 RU RU93051524A patent/RU2106861C1/ru active
- 1992-01-29 MY MYPI92000143A patent/MY110880A/en unknown
- 1992-01-29 HU HU9302212A patent/HU221677B1/hu unknown
- 1992-01-29 WO PCT/GB1992/000163 patent/WO1992013527A1/en not_active IP Right Cessation
- 1992-01-29 CZ CZ19931082A patent/CZ286723B6/cs not_active IP Right Cessation
- 1992-01-29 AT AT92903508T patent/ATE133068T1/de not_active IP Right Cessation
- 1992-01-29 DK DK92903508.7T patent/DK0522128T3/da active
- 1992-01-29 KR KR1019930702233A patent/KR100190254B1/ko not_active IP Right Cessation
- 1992-01-29 UA UA93002090A patent/UA37214C2/uk unknown
- 1992-01-29 AU AU11863/92A patent/AU653203B2/en not_active Expired
- 1992-01-29 PL PL92300134A patent/PL169106B1/pl unknown
- 1992-01-29 CA CA002098108A patent/CA2098108C/en not_active Expired - Lifetime
- 1992-01-29 FR FR9200938A patent/FR2671970B1/fr not_active Expired - Fee Related
- 1992-01-29 GB GB9218097A patent/GB2257363B/en not_active Revoked
- 1992-01-29 ES ES09250043A patent/ES2080641B1/es not_active Expired - Fee Related
- 1992-01-29 SK SK817-93A patent/SK282071B6/sk unknown
- 1992-01-29 ES ES92903508T patent/ES2089498T3/es not_active Expired - Lifetime
- 1992-01-29 CH CH309292A patent/CH685978A5/fr not_active IP Right Cessation
- 1992-01-29 IL IL10079692A patent/IL100796A/en not_active IP Right Cessation
- 1992-01-29 US US08/090,111 patent/US5556639A/en not_active Expired - Lifetime
- 1992-01-29 DE DE4290300T patent/DE4290300T1/de not_active Withdrawn
- 1992-01-29 EP EP92903508A patent/EP0522128B1/en not_active Expired - Lifetime
- 1992-01-29 IE IE920284A patent/IE77165B1/en not_active IP Right Cessation
- 1992-01-29 BE BE9200088A patent/BE1004461A5/fr not_active IP Right Cessation
- 1992-01-29 JP JP04503284A patent/JP3118255B2/ja not_active Expired - Lifetime
- 1992-01-30 MX MX9200412A patent/MX9200412A/es unknown
- 1992-01-30 IT ITRM920069A patent/IT1257473B/it active IP Right Grant
- 1992-02-02 SA SA92120365A patent/SA92120365B1/ar unknown
-
1993
- 1993-06-22 LU LU88323A patent/LU88323A1/fr unknown
- 1993-07-02 NO NO932422A patent/NO306697B1/no not_active IP Right Cessation
- 1993-07-08 SE SE19939302363A patent/SE9302363D0/xx not_active Application Discontinuation
- 1993-07-27 DK DK087893A patent/DK87893A/da not_active Application Discontinuation
- 1993-07-29 FI FI933401A patent/FI111605B/fi active
- 1993-08-26 BG BG98071A patent/BG61665B2/bg unknown
-
1994
- 1994-07-13 AU AU67454/94A patent/AU659581B2/en not_active Expired
- 1994-10-03 US US08/317,300 patent/US5660860A/en not_active Expired - Lifetime
-
1995
- 1995-06-28 HU HU95P/P00506P patent/HU211161A9/hu unknown
- 1995-08-24 PA PA19957695401A patent/PA7695401A1/es unknown
-
1996
- 1996-04-03 GR GR960400936T patent/GR3019545T3/el unknown
-
1997
- 1997-06-12 HK HK78597A patent/HK78597A/xx not_active IP Right Cessation
-
1998
- 1998-02-20 CY CY200798A patent/CY2007A/xx unknown
- 1998-02-27 MY MYPI98000866A patent/MY120025A/en unknown
-
2000
- 2000-03-14 JP JP2000070675A patent/JP3483515B2/ja not_active Expired - Lifetime
-
2002
- 2002-09-24 FI FI20021701A patent/FI20021701A/fi unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK282071B6 (sk) | Tableta dispergovateľná vo vode a spôsob jej prípravy | |
| US5698226A (en) | Water-dispersible tablets | |
| US5629016A (en) | Water-dispersible tablets | |
| US20040197402A1 (en) | Oxcarbazepine dosage forms | |
| PL190988B1 (pl) | Preparat tabletki lub kapsułki do połykania i sposób ich wytwarzania | |
| US4711777A (en) | Pharmaceutical tablets | |
| EP0652752B1 (en) | Water-dispersible tablets | |
| EP0685231B1 (en) | Water-dispersible tablet containing lamotrigine | |
| EP0200252B1 (en) | Tablets comprising trimethoprim and a sulfonamide | |
| GB2278057A (en) | Water -dispersible tablets containing lamotrigine | |
| CZ286719B6 (cs) | Tablety s obsahem lamotriginu dispergovatelné ve vodě | |
| PT101736B (pt) | Comprimidos dispersiveis em agua contendo lamotrigina | |
| NZ241441A (en) | Water-dispersible tablet formulation comprising acyclovir and a swellable clay excipient | |
| PT100197B (pt) | Comprimidos dispersiveis em agua e processo para a sua preparacao |